

France Pirenne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8879154/publications.pdf>

Version: 2024-02-01

41
papers

1,038
citations

686830

13
h-index

433756

31
g-index

46
all docs

46
docs citations

46
times ranked

961
citing authors

#	ARTICLE	IF	CITATIONS
1	First report of a null allele on a <i>CYPB*s</i> background: <i>CYPB*s(37â€‰+â€‰4_8delAGTGA)</i> . <i>Transfusion</i> , 2022, 62, .	0.8	0
2	<i>HLA</i> molecule expression on the surface of cells and microparticles in platelet concentrates. <i>Transfusion</i> , 2021, 61, 1023-1028.	0.8	5
3	Heme control to major B (cell): are you listening?. <i>Blood</i> , 2021, 137, 153-154.	0.6	1
4	Insights into antiâ€‰ formation in carriers of RhD variants through studies of 3D intraprotein interactions. <i>Transfusion</i> , 2021, 61, 1286-1301.	0.8	12
5	Whole-blood phenotyping to assess alloimmunization status in transfused sickle cell disease patients. <i>Blood Advances</i> , 2021, 5, 1278-1282.	2.5	7
6	Wholeâ€‰blood CCR7 expression and chemoattraction in red blood cell alloimmunization. <i>British Journal of Haematology</i> , 2021, 194, 477-481.	1.2	4
7	A Review of the Literature Organized Into a New Database: RHeference. <i>Transfusion Medicine Reviews</i> , 2021, 35, 70-77.	0.9	8
8	<i>RHCE*01 48G</i> & <i>C</i> , <i>366del</i> allele with silenced <i>RHCE*ce</i> expression. <i>Transfusion</i> , 2021, 61, E53-E54.	0.8	0
9	Ex Vivo Activation of Red Blood Cell Senescence by Plasma from Sickle-Cell Disease Patients: Correlation between Markers and Adhesion Consequences during Acute Disease Events. <i>Biomolecules</i> , 2021, 11, 963.	1.8	5
10	How to avoid the problem of erythrocyte alloimmunization in sickle cell disease. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 689-695.	0.9	12
11	Detection and follow-up of a soluble alpha-haemoglobin pool in the red cells of stored blood units. <i>Blood Transfusion</i> , 2021, , .	0.3	0
12	Individual red blood cell fetal hemoglobin quantification allows to determine protective thresholds in sickle cell disease. <i>American Journal of Hematology</i> , 2020, 95, 1235-1245.	2.0	18
13	Dominant immune response to HLAâ€‰B57/B58 molecules after platelet transfusion. <i>Transfusion</i> , 2020, 60, 2807-2814.	0.8	3
14	New molecular basis associated with <i>CD36</i> â€‰negative phenotype in the <i>subâ€‰Saharan African</i> population. <i>Transfusion</i> , 2020, 60, 2482-2488.	0.8	3
15	Cytokine changes in sickle-cell disease patients as markers predictive of the onset of delayed hemolytic transfusion reactions. <i>Cytokine</i> , 2020, 136, 155259.	1.4	2
16	Blood microparticles are a component of immune modulation in red blood cell transfusion. <i>European Journal of Immunology</i> , 2020, 50, 1237-1240.	1.6	10
17	Hemolytic transfusion reactions in sickle cell disease: underappreciated and potentially fatal. <i>Haematologica</i> , 2020, 105, 539-544.	1.7	44
18	Donor-targeted serotherapy as a rescue therapy for steroid-resistant acute GVHD after HLA-mismatched kidney transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 2243-2253.	2.6	11

#	ARTICLE	IF	CITATIONS
19	Complement activation in sickle cell disease: Dependence on cell density, hemolysis and modulation by hydroxyurea therapy. <i>American Journal of Hematology</i> , 2020, 95, 456-464.	2.0	46
20	American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. <i>Blood Advances</i> , 2020, 4, 327-355.	2.5	241
21	The role of Complement in Post-Transfusion Hemolysis and Hyperhemolysis Reaction. <i>Transfusion Medicine Reviews</i> , 2019, 33, 225-230.	0.9	16
22	Identification of genetic biomarkers for alloimmunization in sickle cell disease. <i>British Journal of Haematology</i> , 2019, 186, 887-899.	1.2	14
23	The cause and pathogenesis of hemolytic transfusion reactions in sickle-cell disease. <i>Current Opinion in Hematology</i> , 2019, 26, 488-494.	1.2	10
24	Predisposing factors for anti- α immune response in D ⁺ patients with chronic liver disease transfused with D ⁺ platelet concentrates. <i>Transfusion</i> , 2019, 59, 1353-1358.	0.8	3
25	Control of Humoral Response in Renal Transplantation by Belatacept Depends on a Direct Effect on B Cells and Impaired T Follicular Helper-B Cell Crosstalk. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1049-1062.	3.0	78
26	High immunogenicity of red blood cell antigens restricted to the population of African descent in a cohort of sickle cell disease patients. <i>Transfusion</i> , 2018, 58, 1527-1535.	0.8	13
27	Clinical severity in adult warm autoimmune hemolytic anemia and its relationship to antibody specificity. <i>Haematologica</i> , 2018, 103, e35-e38.	1.7	3
28	Alloimmunization risk associated with amino acid 223 substitution in the RhD protein: analysis in the light of molecular modeling. <i>Transfusion</i> , 2018, 58, 2683-2692.	0.8	9
29	Genotyping in Sickle Cell Disease Patients: The French Strategy. <i>Transfusion Medicine and Hemotherapy</i> , 2018, 45, 264-270.	0.7	16
30	How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions. <i>Blood</i> , 2018, 131, 2773-2781.	0.6	109
31	Red blood cells for transfusion in patients with sepsis: respective roles of unit age and exposure to recipient plasma. <i>Transfusion</i> , 2017, 57, 1898-1904.	0.8	5
32	Anti-CD20 Antibody Prevents Red Blood Cell Alloimmunization in a Mouse Model. <i>Journal of Immunology</i> , 2017, 199, 3771-3780.	0.4	8
33	Design of the DREPAGREFFE trial: A prospective controlled multicenter study evaluating the benefit of genotypical hematopoietic stem cell transplantation over chronic transfusion in sickle cell anemia children detected to be at risk of stroke by transcranial Doppler (NCT 01340404). <i>Contemporary Clinical Trials</i> , 2017, 62, 91-104.	0.8	11
34	Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease. <i>American Journal of Hematology</i> , 2017, 92, 1340-1348.	2.0	85
35	Nonclassical FCGR2C haplotype is associated with protection from red blood cell alloimmunization in sickle cell disease. <i>Blood</i> , 2017, 130, 2121-2130.	0.6	37
36	Evidence of benefits from using fresh and cryopreserved blood to transfuse patients with acute sickle cell disease. <i>Transfusion</i> , 2016, 56, 1730-1738.	0.8	12

#	ARTICLE	IF	CITATIONS
37	Delayed hemolytic transfusion reaction in adult sickle cell disease: presentations, outcomes, and treatments of 99 referral center episodes. <i>American Journal of Hematology</i> , 2016, 91, 989-994.	2.0	103
38	A diagnostic nomogram for delayed hemolytic transfusion reaction in sickle cell disease. <i>American Journal of Hematology</i> , 2016, 91, 1181-1184.	2.0	35
39	Dense red blood cell and oxygen desaturation in sickle cell disease. <i>American Journal of Hematology</i> , 2016, 91, 1008-1013.	2.0	25
40	Anti-CHI can cause a severe delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease patients. <i>Transfusion</i> , 2016, 56, 1828-1833.	0.8	11
41	TIGIT-positive circulating follicular helper T cells and sickle cell alloimmunization. <i>Haematologica</i> , 2015, 100, 1371-1373.	1.7	3